Loading…
CDMO specializing in manufacturing active pharmaceutical ingredients and intermediates for global drugmakers.
CDMO specializing in manufacturing active pharmaceutical ingredients and intermediates for global drugmakers.
This is the Hong Kong share class of the same company as the Shenzhen listing. Drugmakers hire it first to develop a manufacturing process for a drug in trials, which can lead to long commercial supply contracts if the drug is approved, so orders build over years. COVID-treatment work temporarily boosted its sales.
In one line: A Chinese API/CDMO manufacturer akin to a smaller Lonza.
Moat: narrow (process know-how, customer qualification, scale). Process-chemistry expertise and regulatory-compliant manufacturing scale, hard to switch mid-program.
Headquarters: Tianjin, China · Founded: 1995 · Employees: 10,617
Size Asymchem Laboratories (Tianjin) (6821.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $8.19B, the 192nd largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$128.40 on 6 Nov 2026.
Performance Over six months the shares gained 21.6%, against +6.7% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 23.9% over the last twelve months (peer median +12.8%); the operating margin is 17.2% (peer median 13.8%).
Valuation It trades at 29.2× forward earnings against a peer median of 24.3× (8th cheapest of 15).
Capital Return on invested capital runs 2.5 points above its cost of capital (9.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$8.43B | HK$7.20B | HK$6.21B | HK$8.60B | HK$11.9B |
| Revenue growth | — | +16% | -28% | -28% | — |
| Gross profit | HK$3.93B | HK$2.87B | HK$2.44B | HK$4.23B | HK$5.49B |
| EBITDA | n/a | HK$1.75B | HK$1.23B | HK$2.99B | HK$4.04B |
| Net income | HK$1.34B | HK$1.23B | HK$1.03B | HK$2.51B | HK$3.84B |
| Free cash flow | -HK$809M | HK$358M | HK$303M | HK$2.77B | HK$1.37B |
| Capital expenditure | HK$2.12B | HK$1.38B | HK$1.23B | HK$1.37B | HK$2.50B |
| Total debt | HK$807M | HK$583M | HK$506M | HK$630M | HK$657M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Asymchem Laboratories (Tianjin) 6821.HK | $8.19B | +22% | +24% | 17% | 29.2× | n/a |
| Wuxi Apptec 2359.HK | $66.3B | +40% | +38% | 44% | 20.4× | 8.7% |
| Pharmaron Beijing 3759.HK | $11.3B | +45% | +24% | 14% | 22.9× | n/a |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
| Siegfried SFZN.SW | $3.98B | -10% | +4% | 16% | 17.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6821.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.4% | +4.1% | 2nd lowest of 21 |
| 6-month return | +21.6% | +6.7% | 9th highest of 21 |
| Distance from 52-week high | -27.9% | -13.0% | 8th lowest of 21 |
| Revenue growth (TTM) | +23.9% | +12.8% | 9th highest of 21 |
| Operating margin | 17.2% | 13.8% | 7th highest of 20 |
| Forward P/E | 29.2× | 24.3× | 8th cheapest of 15 |
| ROIC minus cost of capital | +2.5 pp | +1.9 pp | 9th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $8.19B | +22% | +24% | 17% | 29.2× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% | +12.6% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.32B | -2% | +4% | 3% | 11.4× | -10.0% | +8.1% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% | +9.3% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | n/a | -9.1% | +6.6% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 16.4× | 24.9% | +16.6% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 48.4× | 47.5% | +10.0% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $8.69B | -10% | +10% | 6% | 10.4× | 20.5% | +5.8% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | n/a | n/a | n/a |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% | +426.7% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 79.5× | n/a | n/a |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |